Skip to main content
padlock icon - secure page this page is secure

Gender and BCR‐ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia

Buy Article:

$59.00 + tax (Refund Policy)

Achieving a major molecular response (MMR) is the goal of imatinib therapy for chronic myeloid leukemia. However, the association between gender, BCR‐ABL transcript type, and age with MMR is not well understood and often controversial.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: BCR‐ABL; chronic myeloid leukemia; gender; imatinib; major molecular response

Document Type: Research Article

Publication date: April 1, 2016

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more